Talimogene laherparepvec
Imlygic (talimogene laherparepvec) is a gene pharmaceutical. Talimogene laherparepvec was first approved as Imlygic on 2015-12-16. It is used to treat melanoma in the USA. It has been approved in Europe to treat melanoma.
| Trade Name | Imlygic |
|---|---|
| Common Name | Talimogene laherparepvec |
| Indication | melanoma |
| Drug Class |
